Skip to main content
. 2021 Sep 16;53(3):712–721. doi: 10.1007/s11239-021-02562-9

Table 2.

Platelet function parameters in survivors and non-survivors on day 1 of ECMO. Data are presented as mean ± SEM, n = 15 survivors, n = 15 non-survivors; p-values were calculated by an unpaired Student’s t-test. p-values < 0.05 are highlighted in bold. Parameters were recorded as described in the Methods section. ECMO, extracorporeal membrane oxygenation; MFI, mean fluorescence intensity; PLA, platelet leukocyte aggregates

Parameter Survivors Non-Survivors p-value
Baseline CD62P expression (%) 16.7 ± 2.4 16.6 ± 2.7 > 0.99
CD62P + TRAP (%) 74.9 ± 3.9 68.5 ± 4.9 0.32
CD62P + ADP (%) 66.7 ± 6.3 51.3 ± 5.5 0.07
Baseline CD63 expression (%) 12.4 ± 2.0 24.0 ± 2.8 0.003
CD63 + TRAP (%) 47.3 ± 5.4 50.4 ± 3.2 0.63
CD63 + ADP (%) 31.1 ± 4.6 32.8 ± 3.4 0.77
Baseline PAC-1 binding (%) 0.34 ± 0.08 0.27 ± 0.06 0.47
PAC-1 + TRAP (%) 13.8 ± 3.3 5.4 ± 2.1 0.04
PAC-1 + ADP (%) 33.7 ± 6.5 12.3 ± 4.0 0.009
GPVI (MFI) 2,271.0 ± 115.6 2,248.0 ± 162.0 0.91
GPIbα (MFI) 11,440 ± 797.9 12,955 ± 1,006 0.25
Baseline PLA (%) 2.9 ± 0.8 5.8 ± 1.4 0.07
Stimulated PLA (%) 30.4 ± 3.6 28.0 ± 4.0 0.66
Mepacrine Assay - % of baseline MFI after 20 min thrombin stimulation 78.1 ± 2.7 81.4 ± 2.7 0.39
Platelet count x103/µl 142.2 ± 15.8 116.5 ± 30.6 0.46